FDA Drug recall D-0656-2020
Rhino 7 Platinum 30000 Capsules, in blue,orange,black background with red,white,blue,gray text in hologram paper packaging, packaged in 2,…
- FDA Drug
- Class I
- terminated
- Published 2020-01-22
On 2020-01-22 the FDA classified a Class I recall of Rhino 7 Platinum 30000 Capsules, in blue,orange,black background with red,white,blue,gray text in hologram paper packaging, packaged in 2,… by Motto International, citing marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0656-2020 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2019-12-17 |
| Published | 2020-01-22 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Motto International |
| Distribution | TX |
Product
Rhino 7 Platinum 30000 Capsules, in blue,orange,black background with red,white,blue,gray text in hologram paper packaging, packaged in 2, 4, and 10 count blister cards, Motto International, Dallas, TX
Reason
Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil
Identifiers
| code_info | All lots remaining within expiry. |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0656-2020%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.